LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, has expanded the collaboration with the University of Dundee in the UK to perform cell culture experiments as one of the partners engaged in the validation program of the Cellevat3d™ microcarriers in cell and gene therapy, novel vaccines, and stem cell therapy production. These studies will generate results during 2023 and will be finalized in 2024 for the commercial launch of the Cellevat3d™ microcarriers.
In this validation study program, Cellevate will optimize the protocols from lab scale to pilot and to large scale to validate the improvements in productivity and process economy when using Cellevat3d™ microcarriers in AAV (Adeno Associated Virus) and stem cell therapy production. Additionally, benchmarking studies will be performed to compare with other microcarriers on the market as part of this programme.
“We are delighted to be involved in this exciting collaboration with Cellevate, as these nanofiber-based microcarriers hold a great promise by improving and facilitating production while reducing the risk of contamination, which is a perfect combination. In our previous studies, the microcarriers have also shown high transfection efficiency for AAV and virus production and we are looking forward to the next steps in the validation programme”, says Dr Jean-Christophe Bourdon, who is the principal investigator and Researcher and Senior Lecturer at School of Medicine, Dept of Cellular Medicine, University of Dundee, Scotland, UK.
“Extending our collaboration with Dr Jean-Christophe Bourdon and his team at the University of Dundee with evaluation and optimization studies is a natural step since they have been evaluating successfully our Cellevat3d™ nanomaterial for use in biologics production since 2021. Dr Bourdon’s extensive research experience and knowledge in cell culture and virus production is extremely valuable in the validation of the Cellevat3d™ microcarriers in AAV production. In turn, the validation program plays an important role in building the commercialization of Cellevat3d™ microcarriers for bioproduction of new biological drugs in 2024”, says Laura Chirica, CEO, Cellevate.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center. The company founded in 2014, develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of microcarriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ microcarriers products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ microcarriers have a commercial launch and sales start planned for 2024.
For more information, please visit www.cellevate.com.
